SBIR/STTR

NIAMS Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research – SBIR [R43/R44]— To accelerate translation and/or commercialization of musculoskeletal and skin tissue engineering and regenerative medicine research findings, the NIAMS issues this FOA to solicit SBIR grant applications from SBCs that focus on pre-clinical studies with potential to immediately lead to phase I human clinical trials, or on development of pre-clinical animal models to assess safety and efficacy of potential commercial products in musculoskeletal and skin tissue engineering and regenerative medicine. Types of late stage pre-clinical studies responsive to this FOA include, but are not limited to:

• Testing safety and/or efficacy of cell or gene therapies with potential to immediately lead to phase I human clinical trials for arthritis or musculoskeletal or skin diseases or disorders.
• Testing of scaffolds, small molecule drugs, biologics or molecular therapeutics (e.g., antisense oligonucleotides) with potential to immediately lead to phase I human clinical trials to promote the regeneration of bone, cartilage, intervertebral disc, ligament, meniscus, muscle, tendon, or skin tissues.
• Validation of more effective outcome measures for tissue regeneration in vivo using novel technologies to track cell distribution, proliferation and/or differentiation after transplantation into animal models with direct utilities to human clinical trials.

 Letters of Intent Receipt Date(s): October 19, 2009 Application Due Date(s):  November 19, 2009

RFA-AR-10-004

NIH: Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (SBIR [R43/R44])– This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products. Application Due Date(s):  Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm   

Program Announcement Number: PA-09-179  

——————————————————————–

NIH: Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR [R41/R42])–This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-179, which encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Current Closing Date for Applications: May 07, 2012    

Funding Opportunity Number: PA-09-178 

————————————————————————— 

Supplemental Opportunity for SBIR/STTR Memberships in I/UCRCs —NSF invites supplemental requests for Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) grantees to join an Industry/University Cooperative Research Center (I/UCRC). The supplements are intended to accelerate the innovation process by partnering industry-relevant academic research with commercialization focused small business research. The supplements will enable small businesses to purchase annual memberships in I/UCRCs; thus opening the doors to the benefits of the centers’ collaborative research endeavors, which are directed to the needs of specific industries. Please see the “Related URL” section for additional information about this opportunity. Supplement window for this opportunity is from October 1 to May 31 annually.

PD 07-1591 

———————————————————— 

NIH: Noninvasive Assays of Human Oocytes and Preimplantation Embryos (SBIR [R43])– This FOA solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) that propose to establish high resolution, non-invasive assays of single human oocytes and preimplantation embryos that will serve to evaluate the quality and developmental potential of oocytes or embryos produced by in vitro fertilization laboratories. The assays must have certain features such as rapidity, low expense, simple laboratory manipulations and a high level of accuracy. A major goal of this initiative is to encourage and increase the use of single embryo transfers for assisted reproduction. This would reduce health risks to the mother and the offspring that result from multiple pregnancies, thereby reducing the high medical costs associated with these adverse outcomes. Letters of Intent Receipt Date(s): October 13, 2009.        Application Due Date(s):  November 10, 2009

RFA-HD-09-025 

———————————————————— 

Noninvasive Assays of Human Oocytes and Preimplantation Embryos (STTR [R41])— This FOA solicits Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to establish high resolution, non-invasive assays of single human oocytes and preimplantation embryos that will serve to evaluate the quality and developmental potential of oocytes or embryos produced by in vitro fertilization laboratories. The assays must have certain features such as rapidity, low expense, simple laboratory manipulations and a high level of accuracy. A major goal of this initiative is to encourage and increase the use of single embryo transfers for assisted reproduction. This would reduce health risks to the mother and the offspring that result from multiple pregnancies, thereby reducing the high medical costs associated with these adverse outcomes. Letters of Intent Receipt Date(s): October 13, 2009. Application Due Date(s):  November 10, 2009.

RFA-HD-09-024 

————————————————————- 

Department of Homeland Security– Small business concerns with the capability to conduct research or research and development (R/R&D) in any of the topic areas described in Section 8.0 of the attached Solicitation, and commercialize the results of that R&D are encouraged to participate.

• Mobile General Aviation (GA) Aircraft Screener
• Human-Animal Discrimination Capability for Unattended Ground Sensors
• Novel Techniques to Culture Fastidious Bacterial Biological Threat Agents (BTAs) from Limited Forensic Samples
• Software Testing and Vulnerability Analysis
• Novel Diagnostic Imaging System
• Noise Cancellation for Voice Operated Switch (VOX) Communications
• Enhancing Training Effectiveness through Cognitive State Assessment
• Wearable Energy to Power and Operate Responder Tools (Wearable EPORT)

 

May 18, 2009 through July 2, 2009: Phase I Proposals Submitted and Accepted/

July 2, 2009: Deadline for Submission of Phase I Proposals is 4:30 p.m. Eastern Daylight Time

 

Solicitation Number: DHS-SBIR-2009-2